Most people with multidrug-resistant tuberculosis are acquiring it because standard treatment is systematically missing a key form of drug resistance. The problem is that global diagnostics focus on detecting resistance to rifampicin, one of two frontline drugs, but ignore resistance to the other, isoniazid. This means patients whose TB is already resistant to isoniazid receive the wrong treatment, and while on it, their bacteria evolve new resistance to rifampicin—creating full-blown MDR-TB. The researcher will test this hypothesis in Vietnam by tracking whether MDR-TB arises through transmission or through this treatment-driven evolution, and by measuring how often patients with undiagnosed isoniazid resistance go on to develop rifampicin resistance. If the hypothesis holds, the findings could reshape global TB diagnostics and treatment protocols—for instance, by adding isoniazid resistance testing to routine screening and switching patients to MDR-TB therapy earlier. That would slow the rise of MDR-TB without requiring new drugs, simply by using existing tools more intelligently.
View original technical description
Recent data suggests that most isoniazid resistant strains have been circulating for decades. The global diagnostic focus on rifampicin resistance has meant that isoniazid mono-resistant strains are systematically being treated with first-line therapy. With MDR-TB incidence rising despite overall TB incidence falling, the concern is that we are selecting for rifampicin resistance. The alternative explanation, that MDR-TB is transmitting more successfully, seems unlikely, but possible. The hypothesis I will test is that most isoniazid resistance is acquired through transmission whereas most rifampicin resistance evolves de novoin patients with undiagnosed, pre-existing isoniazid resistance. I will investigate the following research questions in Vietnam: (i) What is the proportion of transmitted versus newly evolved MDR-TB? (ii) What is the prevalence of isoniazid resistance among patients never previously exposed to the drug, and what proportion of patients with unsuccessful treatment outcomes evolve isoniazid resistance? (iii) What is the risk of evolving rifampicin resistance by treating isoniazid resistant strains with first-line drugs? What proportion of patients who evolve rifampicin resistance after exposure to first-line drugs also evolved isoniazid resistance? (iv) Do host genotype and variable anti-tuberculosis drug pharmacokinetics contribute to evolving drug resistance? The findings will inform policy on diagnostics, treatment protocols and disease control.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know